NCT04300998 Study of CAR-T Therapy in Older Patients
| NCT ID | NCT04300998 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Memorial Sloan Kettering Cancer Center |
| Condition | Lymphoma |
| Study Type | OBSERVATIONAL |
| Enrollment | 154 participants |
| Start Date | 2020-03-04 |
| Primary Completion | 2027-03-04 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 154 participants in total. It began in 2020-03-04 with a primary completion date of 2027-03-04.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study is being done to find out how older patients respond to CAR-T cell therapy and how the treatment affects their quality of life. This is a quality of life study and participating in the study does not involve receiving any treatment, other than the standard treatment for participants' disease.
Eligibility Criteria
Inclusion Criteria: * are ≥60 years old (all cohorts) * have pathologically confirmed, relapsed refractory lymphoid malignancy or plasma cell disorder receiving a commercial CAR T-cell product (all cohorts) * able to speak and understand English (cohort 1 and 4 only) * have a MoCA score of less than 26 out of 30 during the GA visit by a geriatrician prior to CAR T-cell treatment (cohort 4 only) Exclusion Criteria: * Any prior commercial or investigational CAR T therapy (all cohorts) * Current diagnosis of major Axis I psychiatric disorder (DSM-IV), major depression, bipolar disorder, or schizophrenia, as per medical records or patient report (cohort 1 only) * History of a neurological disorder, neurodegenerative disease, or traumatic brain injury with loss of consciousness (\>60 minutes), as per medical records or patient report (cohort 1 only) * Current ongoing substance abuse and/or history of substance abuse, as per medical records or patient report (cohort 1 only) * History of CNS disease (cohort 4 only)
Contact & Investigator
Richard Lin, MD, PhD
PRINCIPAL INVESTIGATOR
Memorial Sloan Kettering Cancer Center
Frequently Asked Questions
Who can join the NCT04300998 clinical trial?
This trial is open to participants of all sexes, aged 60 Years or older, studying Lymphoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT04300998 currently recruiting?
Yes, NCT04300998 is actively recruiting participants. Contact the research team at ABMTTrials@mskcc.org for enrollment information.
Where is the NCT04300998 trial being conducted?
This trial is being conducted at New York, United States.
Who is sponsoring the NCT04300998 clinical trial?
NCT04300998 is sponsored by Memorial Sloan Kettering Cancer Center. The principal investigator is Richard Lin, MD, PhD at Memorial Sloan Kettering Cancer Center. The trial plans to enroll 154 participants.